Zimmer Biomet has established itself as one of the largest players in the orthopedic medtech space and has strengthened its position with several high-profile acquisitions.
On top of its acquisitions, in June 2026 the company secured $2.75 billion through two new revolving credit agreements.
Here are four major acquisitions totaling more than $1.5 billion made by Zimmer Biomet since 2023:
- Zimmer Biomet agreed to acquire an FDA-approved pain relief device for osteoarthritis and knee pain from Pacira BioSciences for $140 million.
- Zimmer Biomet entered into a definitive agreement to acquire Monogram Technologies, an orthopedic robotics company, for $177 million.
- The company completed its acquisition of Paragon 28, a medical device company in the foot-and-ankle orthopedic sector. Zimmer Biomet acquired all of Paragon 28’s outstanding shares for $13 per share, corresponding to an equity value of about $1.1 billion.
- Zimmer Biomet signed an agreement to acquire Embody, an orthobiologics company, for $155 million.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.